09:15am Thursday 19 October 2017

New method for understanding neurodegenerative diseases

A large scale analyses of neuronal proteins sheds light on the mechanisms underlying neurodegenerative disease.

One of the early signs of diseases like Alzheimer’s or Parkinson’s is that the junctions between nerve cells – called synapses – are damaged, thereby disrupting neuronal communication. A new molecular genetic study provides insights into what may make synapses so vulnerable.

For the first time researchers have used proteomics to profile the protein content of differentially synapses in a mouse model of a juvenile form of a degenerative disorder called neuronal ceroid lipofuscinosis (NCL). The term NCL encompasses a group of disorders which collectively represent the most frequent form of dementia in childhood.

The authors found that perturbations in signalling pathways involved in the degradation of the amino acid valine and the rearrangement of the cytoskeleton correlate with synaptic vulnerability.

Their results show that combining genetic and pharmacological targeting of key signalling proteins at an early stage of disease progression in simplistic model systems can contribute to further our understanding of the mechanisms underlying neurodegenerative disease and identify new potential therapeutic targets for future examination.

“This study represents further proof of principle that an approach combining such disparate tools and techniques is likely to provide, and is potentially necessary for, identification of novel factors which are capable of regulating the stability of the nervous system in health and disease” said Dr Tom Wishart, The Roslin Institute.

Original publication

The work – published in the journal Scientific Reports – was carried out by researchers from The Roslin Institute, Centre for Integrative Physiology and Euan MacDonald Centre for Motor Neurone Disease Research – The University of Edinburgh, Institute for Science and Technology in Medicine – Keele University, Psychology & Neuroscience – King’s College London, and Los Angeles Biomedical Research Institute and David Geffen School of Medicine – University of California Los Angeles.

The study was supported by the Biotechnology and Biological Sciences Research Council, the Euan MacDonald Centre, The Darwin Trust of Edinburgh, the Batten Disease Support and Research Association and the RJAH Institute of Orthopaedics.

Maica Llavero Hurtado, Heidi R. Fuller, Andrew M. S. Wong, Samantha L. Eaton, Thomas H. Gillingwater, Giuseppa Pennetta, Jonathan D. Cooper & Thomas M. Wishart (2017) Proteomic mapping of differentially vulnerable pre-synaptic populations identifies regulators of neuronal stability in vivoScientific Reports 7, 12412. DOI: 10.1038/s41598-017-12603-0.

 

About BBSRC

BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

 


Share on:
or:

MORE FROM Medical Breakthroughs

Health news